Semaglutide Appears Promising in NASH |
Clinical News
eMediNexus Coverage from: 
Semaglutide Appears Promising in NASH

0 Read Comments                

Nearly 60% of patients with biopsy-confirmed nonalcoholic steatohepatitis and liver fibrosis reported NASH resolution following treatment with semaglutide, suggested a phase 2, double-blind, randomized, placebo-controlled trial.

Around 40% of patients treated with 0.1mg semaglutide, 36% given 0.2mg, and 59% receiving 0.4mg semaglutide achieved NASH resolution with no worsening of fibrosis, compared to 17% of those receiving placebo (odds ratio, 6.87;P< .001 for the highest semaglutide dose). There were no significant between-group differences in the secondary endpoint (improvement of fibrosis by at least one stage without worsening of NASH), which was evident in 43% of patients on the highest semaglutide dose compared to 33% in the placebo group (OR, 1.42; P= .48). The findings are published in the New England Journal of Medicine and were presented at the 2020 American Association for the Study of Liver Diseases (AASLD) meeting… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now